CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Jun 28 2013
By Bennett, Nancy M. ; Pilishvili, Tamara ; Whitney, Cynthia G. ; ...
Source: MMWR Morbidity Mortal Weekly Rep. 2013; 62(25):521-524.
Series: Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

Details Supporting Files You May Also Like

Details:

Journal Article:

Morbidity and Mortality Weekly Report (MMWR)
Personal Author:

Bennett, Nancy M. ; Pilishvili, Tamara ; Whitney, Cynthia G. ; Moore, Matthew ; Gierke, Ryan ; ... More +

Bennett, Nancy M. ; Pilishvili, Tamara ; Whitney, Cynthia G. ; Moore, Matthew ; Gierke, Ryan ; Harris, Aaron M. Less -
Corporate Authors:

United States. Advisory Committee on Immunization Practices.
Description:

On February 20, 2013, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for children aged 6-18 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants who have not previously received PCV13. PCV13 should be administered to these children regardless of whether they received the 7-valent pneumococcal conjugate vaccine (PCV7) or the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Recommendations for PPSV23 use for children in this age group remain unchanged. The evidence for the benefits and risks associated with PCV13 vaccination of children with immunocompromising conditions was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This recommendation reflects a policy change from permissive and off-label recommendation of PCV13 in the pediatric immunocompromised population to a category A recommendation. This report summarizes the evidence considered by ACIP to make this recommendation and reviews the recommendations for use of PCV13 and PPSV23 for children aged 6-18 years.
Subjects:

[+]

Adolescent Advisory Committees Articles Child Humans Immunocompromised Host Pneumococcal Infections Pneumococcal Vaccines Randomized Controlled Trials As Topic Risk Assessment Vaccines, Conjugate
Source:

MMWR Morbidity Mortal Weekly Rep. 2013; 62(25):521-524.
Series:

Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
ISSN:

0149-2195 (print);1545-861X (digital);
Pubmed ID:

23803961
Pubmed Central ID:

PMC4604951
Document Type:

Journal Article
Place as Subject:

United States
Location:

North America
Pages in Document:

4 pdf pages
Volume:

62
Issue:

25
Collection(s):

Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha-512:66fb1e8a0b88db93bb22db5e79f7023c4f4a9a9544a5b282dd5cc01607a4c43ec9b8ff539243d3166789f1bbf2193bed464a1ec662ea84440f666054c1b594fa
Download URL:

https://stacks.cdc.gov/view/cdc/57063/cdc_57063_DS1.pdf
File Type:

[PDF-203.50 KB]

	521-524.nxml	xml
	521-524f1.gif	gif
	521-524f1.jpg	jpeg